Chemours (NYSE: CC) reported Q4 EPS of $0.11, $0.01 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.37 billion.

Full Year 2025 Outlook

The Company expects to deliver 2025 Adjusted EBITDA of $825 million to $975 million. Operating cash flow is expected to improve as the year progresses and more than fund anticipated capital expenditures ranging from $250 million to $300 million, while also ensuring dividend funding, subject to Board approval quarterly.

For earnings history and earnings-related data on Chemours (CC) click here.